Jun 8, 2026 – 8.12pmNavis Capital Partners’ medical supplies business Device Technologies is in the running to win the top gong for 2026’s most stealthy – and protracted – sale process.It was Kuala Lumpur-headquartered Navis’ biggest deal globally in 2018. The business’s EBITDA had doubled to more than $100 million as of last year when country head Phil Latham hired Morgan Stanley, Jefferies Australia and Gilbert + Tobin to explore an exit.Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
Blackstone gets ducks in a row for slow-moving Device Tech sale
The PE giant, led locally by Michael Blickstead, is flush with cash after raising $US13.1 billion for its largest-ever Asia fund last week.
165 words~1 min read
